Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Strontium ranelate: a physiological approach for optimizing bone formation and resorption.

P J Marie1

  • 1INSERM U606 and University Paris 7, Lariboisière Hospital, 2 rue Ambroise Paré, 75475 Paris cedex 10, France. pierre.marie@larib.inserm.fr

Bone
|January 28, 2006
PubMed
Summary

Strontium ranelate, a novel osteoporosis drug, uniquely enhances bone formation while reducing bone resorption. Clinical trials show it improves bone mass by balancing these effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endothelin-1 Augments Therapeutic Potency of Human Mesenchymal Stem Cells via CDH2 and VEGF Signaling.

Molecular therapy. Methods & clinical development·2019
Same author

Zinc chelation: a metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance.

Cell death & disease·2013
Same author

E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis.

Cell death & disease·2013
Same author

Cell and gene therapy for bone repair.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2011
Same author

[CT scan, MR imaging and anatomopathologic correlation in the glottic carcinoma T1-T2].

Revue de laryngologie - otologie - rhinologie·2010
Same author

How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2010

Area of Science:

  • Pharmacology
  • Bone Biology
  • Osteoporosis Research

Background:

  • Estrogen deficiency-induced osteoporosis involves an imbalance between bone resorption and formation, leading to bone deterioration.
  • Current anti-osteoporotic therapies are typically anticatabolic or anabolic, but not both.
  • Strontium ranelate represents a novel therapeutic approach with a dual mode of action.

Purpose of the Study:

  • To investigate the dual action of strontium ranelate on bone resorption and formation.
  • To evaluate the efficacy of strontium ranelate in preclinical models and clinical trials for osteoporosis.

Main Methods:

  • In vitro studies on bone cells to assess effects on osteoclasts and preosteoblastic cells.
  • In vivo studies in intact, immobilized, and ovariectomized animal models.

Related Experiment Videos

  • Clinical trials (Spinal Osteoporosis Therapeutic Intervention [SOTI]) measuring bone turnover markers.

    • Main Results:

    • In vitro: Strontium ranelate decreased osteoclast resorption and enhanced preosteoblastic cell proliferation and collagen synthesis.
    • In vivo: Strontium ranelate increased bone mass in mice, reduced bone loss in immobilized rats, and prevented bone loss in ovariectomized rats.
    • Clinical trials: Increased bone alkaline phosphatase and decreased C-terminal telopeptide of type I collagen (CTX) in treated patients.

    Conclusions:

    • Strontium ranelate exhibits a unique dual mechanism of action, increasing bone formation and decreasing bone resorption.
    • These effects translate to improved bone mass and prevention of bone loss in various models and human patients.
    • Strontium ranelate is a promising therapeutic agent for managing osteoporosis.